Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ: ATRC )

32.76 +0.07 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
AtriCure to Announce Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
What 7 Analyst Ratings Have To Say About AtriCure
Via Benzinga
AtriCure Reports First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
Via Benzinga
Earnings Outlook For AtriCure
Via Benzinga
5 Analysts Have This to Say About AtriCure
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
Via Benzinga
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
From AtriCure, Inc.
Via Business Wire
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure: Q2 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
AtriCure Reports Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure to Announce Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback